title: Erlotinib: A successful clinical case and some notes about hepatic toxicity.
abstract: A case of a woman with lung adenocarcinoma in which fifteen-month disease control was achieved with second-line erlotinib treatment is presented. Five months after treatment beginning, isolated grade 3 hyperbilirubinemia occurred and daily dose was reduced to 100mg. Comments on erlotinib hepatic toxicity and the pharmacologic interactions on erlotinib metabolism are given. Rev Port Pneumol 2008; XIV (Supl 3): S29-S34.
authors.affiliation: Assistente Hospitalar Graduado. Unidade de Oncologia Pneumológica. Hospital Pulido Valente. Centro Hospitalar Lisboa Norte, EPE. Electronic address: agostinhomatoscosta@gmail.com.
authors.forename: Agostinho
authors.initials: A
authors.lastname: Costa
keywords: Erlotinib; hepatic toxicity; hiperbilirrubinemia; hyperbilirubinemia; interacções farmacológicas; pharmacologic interactions; toxicidade hepática